Tricida (NASDAQ: TCDA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.700 | -0.400 | 0.3000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Tricida (NASDAQ: TCDA) through any online brokerage.
Other companies in Tricida’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), CinCor Pharma (NASDAQ:CINC) and Sundial Growers (NASDAQ:SNDL).
The latest price target for Tricida (NASDAQ: TCDA) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 16.00 expecting TCDA to rise to within 12 months (a possible 65.98% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Tricida (NASDAQ: TCDA) is $9.64 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Tricida.
Tricida’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Tricida.
Tricida is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.